Integrative Molecular Characterization and Biomarker Validation in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

  • Hamid, Anis (Primary Chief Investigator (PCI))
  • Sweeney, Christopher J. (Chief Investigator (CI))
  • Corcoran, Niall (Chief Investigator (CI))
  • Davis, Ian (Chief Investigator (CI))
  • Van Allen, Eliezer M (Chief Investigator (CI))
  • Attard, Gerhardt (Chief Investigator (CI))
  • Azad, Arun (Chief Investigator (CI))
  • Wang, Xin Victoria (Chief Investigator (CI))

Project: Research

Project Details

Project Description

The aims of this project are: Aim 1: To determine whether TSG alterations are prognostic and/or predictive of outcome with ADT or ADT plus docetaxel in the CHAARTED, STAMPEDE and ENZAMET trials, through exome sequencing. Aim 2: To determine whether the PAM50 luminal-basal classifier is associated with differential prognosis with ADT alone and altered benefit from ADT plus docetaxel in the CHAARTED, STAMPEDE and ENZAMET trials, through whole transcriptome profiling. Aim 3: To build and validate prognostic and predictive clinicogenomic models of mHSPC leveraging molecular data from CHAARTED, STAMPEDE and ENZAMET.
StatusActive
Effective start/end date1/09/2131/08/25